

Short-Course High-Intensity Statin Treatment during Admission for Myocardial Infarction and LDL-Cholesterol Reduction—Impact on Tailored Lipid-Lowering Therapy at Discharge

Víctor Marcos-Garcés ^{1,2,*}, Héctor Merenciano-González ^{1,2}, María Luz Martínez Mas ¹, Patricia Palau ^{1,2,3}, Josefa Inés Climent Alberola ⁴, Nerea Perez ², Laura López-Bueno ⁴, María Concepción Esteban Argente ⁴, María Valls Reig ¹, Raquel Muñoz Alcover ¹, Inmaculada Pradillas Contreras ¹, Ana Arizón Benito ⁵, Alfonso Payá Rubio ⁴, César Ríos-Navarro ², Elena de Dios ⁶, Jose Gava ⁷, Francisco Javier Chorro ^{1,2,3,6}, Juan Sanchis ^{1,2,3,6} and Vicente Bodi ^{1,2,3,6,*}

¹ Department of Cardiology, Hospital Clinico Universitario de Valencia, 46010 Valencia, Spain; hectormeren@gmail.com (H.M.-G.); mluzmmas@comv.es (M.L.M.M.); patricia.palau@uv.es (P.P.); mvallsr@gmail.com (M.V.R.); raquelalcover@hotmail.com (R.M.A.); inmapracon@yahoo.es (I.P.C.); francisco.j.chorro@uv.es (F.J.C.); sanchis_juafor@gva.es (J.S.)

² INCLIVA Health Research Institute, 46010 Valencia, Spain; neere_8@hotmail.com (N.P.); cesar.rios@uv.es (C.R.-N.)

³ Department of Medicine, Faculty of Medicine and Odontology, University of Valencia, 46010 Valencia, Spain

⁴ Department of Rehabilitation, Hospital Clinico Universitario de Valencia, 46010 Valencia, Spain; inescliment093@gmail.com (J.I.C.A.); laura.lopez@uv.es (L.L.-B.); lulilloluli@yahoo.es (M.C.E.A.); paya_alf@gva.es (A.P.R.)

⁵ Hospital Clinico Universitario de Valencia, 46010 Valencia, Spain; arizon_anaben@gva.es

⁶ Network Biomedical Research Center for Cardiovascular Diseases (CIBER-CV), 28029 Madrid, Spain; elenaddll@gmail.com

⁷ Centre for Biomaterials and Tissue Engineering, Universitat Politècnica de València, 46022 Valencia, Spain; jose_4_6_90@hotmail.com

* Correspondence: marcos_vic@gva.es (V.M.-G.); vicente.bodi@uv.es (V.B.)

1. Supplementary Tables

Table S1. Estimated percentage of LDL-C reduction according to LLT.

LLT	% reduction in mono-therapy	% reduction in combination with ezetimibe 10mg o.d.
Rosuvastatin 5mg o.d.	40	54
Rosuvastatin 10mg o.d.	46	58
Rosuvastatin 20mg o.d.	51	62
Rosuvastatin 30mg o.d.	54	65
Rosuvastatin 40mg o.d.	56	66
Atorvastatin 10mg o.d.	37	51
Atorvastatin 20mg o.d.	43	56
Atorvastatin 30mg o.d.	46	58
Atorvastatin 40mg o.d.	49	61
Atorvastatin 80mg o.d.	55	65
Simvastatin 5mg o.d.	24	41
Simvastatin 10mg o.d.	28	45
Simvastatin 20mg o.d.	33	48

Simvastatin 40mg o.d.	39	53
Simvastatin 80mg o.d.	44	57
Pravastatin 10mg o.d.	20	38
Pravastatin 20mg o.d.	26	43
Pravastatin 40mg o.d.	29	45
Pravastatin 80mg o.d.	35	50
Pitavastatin 1mg o.d.	32	48
Pitavastatin 2mg o.d.	36	51
Pitavastatin 4mg o.d.	43	56
Fluvastatin 20mg o.d.	20	38
Fluvastatin 40mg o.d.	24	41
Fluvastatin 80mg o.d.	34	49
Lovastatin 10mg o.d.	20	38
Lovastatin 20mg o.d.	28	45
Lovastatin 40mg o.d.	31	47
Lovastatin 80mg o.d.	40	54
Ezetimibe 10mg o.d.	23	-
Evolocumab 140mg o.d.	+61% reduction	+70% reduction
Alirocumab 75mg o.d.	+53% reduction	+64% reduction
Alirocumab 150mg o.d.	+62% reduction	+71% reduction

Abbreviations: LDL-C = low-density lipoprotein cholesterol. LLT = lipid-lowering therapy.